LIFE:NGS-aTyr Pharma Inc.

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 3.79

Change

+0.67 (+21.47)%

Market Cap

USD 0.08B

Volume

0.12M

Analyst Target

USD 3.50
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

aTyr Pharma Inc is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its knowledge of Physiocrine biology, a newly discovered set of physiological modulators.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-10-16 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

-4.15 (-1.02%)

USD 107.38B
REGN Regeneron Pharmaceuticals Inc

-0.78 (-0.09%)

USD 106.98B
MRNA Moderna Inc

+0.96 (+0.89%)

USD 38.83B
ARGX argenx NV ADR

-0.08 (-0.02%)

USD 22.20B
BNTX BioNTech SE

-0.40 (-0.45%)

USD 21.93B
GMAB Genmab AS

-0.09 (-0.32%)

USD 19.78B
ALNY Alnylam Pharmaceuticals Inc

-2.27 (-1.55%)

USD 18.47B
RPRX Royalty Pharma Plc

+0.16 (+0.58%)

USD 18.18B
BGNE BeiGene Ltd

+5.13 (+3.69%)

USD 16.99B
BMRN Biomarin Pharmaceutical Inc

-0.86 (-0.93%)

USD 16.06B

ETFs Containing LIFE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 664.58% 100% F 99% N/A
Dividend Return N/A N/A N/A N/A F
Total Return 664.58% 100% F 99% N/A
Trailing 12 Months  
Capital Gain 439.89% 99% N/A 99% N/A
Dividend Return N/A N/A N/A N/A F
Total Return 439.89% 99% N/A 99% N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A F
Dividend Return N/A N/A N/A N/A F
Total Return N/A N/A N/A N/A F
Average Annual (5 Year Horizon)  
Capital Gain -7.64% 43% F 23% F
Dividend Return -7.64% 43% F 22% F
Total Return N/A N/A N/A N/A F
Risk Return Profile  
Volatility (Standard Deviation) 112.66% 13% F 6% D-
Risk Adjusted Return -6.78% 52% F 32% F
Market Capitalization 0.08B 10% F 11% F

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio 0.46 90% 89%
Price / Cash Flow Ratio -0.49 15% 63%
Price/Free Cash Flow Ratio 0.48 10% 44%
Management Effectiveness  
Return on Equity -67.25% 49% 17%
Return on Invested Capital -49.11% 55% 17%
Return on Assets -25.79% 58% 17%
Debt to Equity Ratio 24.56% 42% 59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.